Skip to content

In the BioHarmony Drug Report Database


Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Trade Name Waylivra
Common Name Volanesorsen
Indication hyperlipoproteinemia type i
Drug Class Antisense oligonucleotides
Get full access now